Company intelligence / Profile preview
Taizhou Mabtech Pharmaceutical
Taizhou, Jiangsu, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Taizhou Mabtech Pharmaceutical is a leading Chinese biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of monoclonal antibody drugs and biosimilars. The company has three core products approved for marketing in China as of 2024—CMAB009/cetuximab β injection for first-line therapy of RAS/BRAF wild-type mCRC; CMAB008/infliximab biosimilar for autoimmune diseases; omalizumab biosimilar for allergic asthma—and several other candidates at NDA/BLA or clinical stages. Its products are widely distributed across China with growing international registration efforts. The company operates large-scale GMP-compliant manufacturing facilities with significant capacity expansion underway.
- Therapeutic areas
- GastroenterologyRheumatologyImmunologyEndocrinologyDermatologyOncology
- Modalities
- Monoclonal antibodyBiosimilarAntibody-drug conjugate (ADC)Recombinant protein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Simcere Zaiming/Simcere Pharmaceutical Group Ltd.: exclusive commercial rights to anti-EGFR mAb CMAB009 in ChinaKexing Biopharm Co., Ltd.: exclusive promotion agreement for infliximab product CMAB008 類停® within mainland China
Beyond the preview
Go deeper on Taizhou Mabtech Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taizhou Mabtech Pharmaceutical.